Eli Lilly (LLY)

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Wall Street Mostly Lower Amid Trump-Fed Tensions, Nvidia’s Continued Slide

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025.

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Thursday. Stay informed about the market activity below.

Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive momentum in trade negotiations.

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed significantly well in helping patients manage obesity and diabetes. The stock's reaction suggested that investors were optimistic that, if approved, Lilly could scale production quickly and tap into the fast-growing diabetes and obesity markets.

Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by 2030.

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

While the S&P 500 includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Before this, Nvidia’s H100 and A100 chips, which are more powerful than the H20 chip, were banned from being sold in China.

The central bank acknowledged that the euro area economy has been building up some resilience against global shocks, but the growth outlook has deteriorated due to rising trade tensions.

The company says orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial.

Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles.

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable safety profile.

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment.

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington